Each vial of lyophilized powder for injection contains:
Tenoxicam ………………………………………………….20 mg
Excipients q.s to ………………………………………….. 1 vial
Each solvent ampoule contains:
Water for injection q.s to ………………………………. 2ml
Lyophilized powder for injection
Box of 01 vial and 01 solvent ampoule
Tenoxicam is for patients considered unable to take oral tenoxicam for the relief of pain and inflammation in osteoarthritis and rheumatoid arthritis and for the short-term management of acute musculoskeletal disorders including strains, sprains andother soft-tissue injuries.
Store in tight vial at the temperature below 30ºC, protect from light.
– TENOXICAM 20 should be given by IV or IM.
– A single daily dose of 20 mg for one to two days initially to be continued with the oral form, with administration at the same time each day.
– In acute musculoskeletal disorders treatment should not normally be required for more than 7 days, but in severe cases it may be continued up to a maximum of 14 days.
– Higher doses should be avoided as they do not usually achieve significantly greater therapeutic effect but may be associated with a higher risk of adverse events.
– The lyophilisate should be dissolved in 2 ml of sterile water forinjections and the reconstituted solution should be used immediately.
* In the elderly
The elderly are at increased risk of serious adverse reactions. They are also more likely to be receiving concomitant medication or to have impaired hepatic, renal or cardiovascular function. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.
* Use in renal and hepatic insufficiency
+ Creatinine clearance greater than 25 ml/min: Usual dosage but monitor patients carefully.
+ Creatinine clearance less than 25 ml/min: Insufficient data to make dosage recommendations
Please read carefully the leaflet before using
